>to gather additional safety and efficacy data vs Hepsera?<
I’m not asking why Hepsera is in the control arms. The question I’m asking is why only one of the four arms—the Hepsera arm in the e- trial—is different from the other three arms in that it does not stop treatment to test for SVR.
Market Data 
Markets 
AI
